Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
Merus N.V. - Common Shares (MRUS)
Last merus n.v. - common shares earnings: 8/19 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/mrus
Company Research
Source: GlobeNewswire
- Petosemtamab in 1L HNSCC in combination with pembrolizumab initial interim clinical data planned for 2Q24; preparing for a potential phase 3 trial - Petosemtamab in 2L+ HNSCC phase 3 trial planned to initiate mid-2024; interim clinical data planned for 2H24 - Petosemtamab in 2L CRC: cohort planned to initiate in 2024 - Zeno in NRG1+ cancer: Sufficient clinical data expected in 1H24 to support potential BLA submissions - Based on the Company’s current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus’ operations into 2027 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the fourth quarter and full year and provided a business update. “2024 is poised to be a transformati
Show less
Read more
Impact Snapshot
Event Time:
MRUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRUS alerts
High impacting Merus N.V. - Common Shares news events
Weekly update
A roundup of the hottest topics
MRUS
News
- Merus (NASDAQ: MRUS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $66.00 price target on the stock.MarketBeat
- Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDAGlobeNewswire
- Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $65.00 price target on the stock.MarketBeat
- Merus Announces Financial Results for the First Quarter 2024 and Provides Business UpdateGlobeNewswire
MRUS
Earnings
- 5/8/24 - Beat
MRUS
Sec Filings
- 5/10/24 - Form 8-K/A
- 5/9/24 - Form 4
- 5/9/24 - Form 4
- MRUS's page on the SEC website